Clinical Study
Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients
Table 4
The laboratory data of the patients in both naltrexone and placebo groups.
| | | Total | NLTX | Placebo | P | | | Mean ± SD | Median (range) | Mean ± SD | Median (range) | Mean ± SD | Median (range) |
| | WBC ×106 µL | | 11.0 (34 to 21.7) | | 10.1 (34 to 17) | | 11.4 (65 to 2.17) | 0.12† | | RBC ×106 µL | | 4.56 (3.87 to 5.9) | | 4.62 (3.87 to 5.52) | | 4.51 (3.91 to 5.9) | 0.40† | | Hb (mg/dL) | | 13.4 (1.3 to 16.6) | | 14.1 (9.1 to 16.2) | | 12.4 (1.3 to 16.6) | 0.10† | | Hct (%) | | 39 (30.1 to 49.8) | | 40.3 (30.1 to 48.4) | | 39 (34 to 49.8) | 0.64‡ | | Platelet ×103 µL | | 225 (46 to 599) | | 232 (97 to 599) | | 220 (46 to 396) | 0.53† | | Blood sugar (mg/dL) | | 106 (50 to 317) | | 91 (53 to 197) | | 118 (50 to 317) | 0.03‡ | | Blood urea (mg/dL) | | 24 (15 to 69) | | 24 (15 to 47) | | 26 (15 to 69) | 0.35‡ | | Creatinine (mg/dL) | | 0.9 (0.6 to 3) | | 0.9 (0.6 to 1.5) | | 0.9 (0.6 to 3) | 0.13‡ | | SGOT (U/L) | | 22 (11 to 241) | | 18 (12 to 63) | | 25 (11 to 241) | 0.04‡ | | SGPT (U/L) | | 18 (5 to 167) | | 16 (10 to 105) | | 21 (5 to 167) | 0.58‡ | | LDH (U/L) | | 422 (216 to 2780) | | 416 (290 to 2780) | | 422 (216 to 1324) | 0.26‡ | | CPK (U/L) | | 110 (50 to 4450) | | 99 (59 to 170) | | 144 (50 to 4450) | 0.04† | | ALP (U/L) | | 175 (11 to 320) | | 178 (98 to 310) | | 172 (11 to 320) | 0.80† | | Na (mEq/L) | | 139 (132 to 1346) | | 139 (132 to 1346) | | 140 (136 to 147) | 0.73‡ | | K (mEq/L) | | 4 (3.4 to 4.8) | | 4 (3.4 to 4.6) | | 4.1 (3.4 to 4.8) | 0.17† | | Bili. T (mg/dL) | | 0.5 (0 to 1.4) | | 0.5 (0 to 1.4) | | 0.5 (0 to 1.4) | 0.62‡ | | Bili. D (mg/dL) | | 0.2 (0.1 to 1) | | 0.2 (0.1 to 1) | | 0.1 (0.1 to 0.3) | 0.02‡ |
|
|
Based on Student’s t-test. ‡Based on Mann-Whitney U test.
|
